Contract development and manufacturing organization Lonza has completed the expansion of its highly potent API (HPAPI) multipurpose suite in Visp, Switzerland. The expansion gives Lonza additional development and manufacturing capacity for antibody-drug conjugates (ADC) payloads. The site includes a range of equipment for manufacturing payload linkers.
Divided into cleavable and non-cleavable types, linkers are a vital component of ADCs as they connect an antibody with a drug (payload) through a chemical bond.
Lonza anticipates that the ADC market will grow swiftly, given the demand for novel targeted cancer therapeutics.
The company has announced a series of expansions in recent years, including investing in upgraded drug manufacturing services last year.
To learn more about the most recent expansion, we reached out to Lonza’s Giovanna Libralon, senior director, commercial development, small molecules and Iwan Bertholjotti, senior director, comme…